A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Sponsor
Hoffmann-La Roche
Study ID
NCT01996332
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated time on study treatment is 3-12 months.

Key Dates

First listed
Nov 27, 2013
Start date
Apr 30, 2004
Status verified
Jun 2014
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
1,805 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tarceva Arm

Primary Outcome Measure

Time to Disease Progression or Death by Line of Treatment [ Time Frame: Baseline, every 6-8 weeks up to 3 years until disease progression or death ]

Related Studies